Market access roundup: Government grillings for Vertex and US pharmaIt was a month characterised by governments butting heads with pharma over pricing both in the UK and Share XMarket access roundup: Government grillings for Vertex and US pharmahttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-government-grillings-vertex-us-pharma-pricing/
Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drugUS Senator Bernie Sanders says the FDA should allow pharmacies and generic manufacturers to make low-cost copies of Share XSanders calls on FDA to allow low-cost rivals to $375k Catalyst drughttps://pharmaphorum.com/news/sanders-calls-on-fda-to-allow-low-cost-rivals-to-375k-catalyst-drug/
Catalyst sparks price row in US with $300,000 rare disease drugThe controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share XCatalyst sparks price row in US with $300,000 rare disease drughttps://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
